Undetectable serum prostate-specific antigen associated with metastatic prostate cancer: A case report and review of the literature

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 4, 1998, Pages 323-326

  Safa, Afshin A ^a,b   Reese, David M ^a   Carter, Diane M ^a   Phillipson, Julia ^a   Smith, Robert ^a   Dougherty, Shona ^a  

^a UCLA MEDICAL CENTER   (United States)

^b Department of Radiation Oncology ^*  (United States)

Author keywords

Metastasis; Prostate cancer; Prostate specific antigen; Prostatic acid phosphatase; Radical prostatectomy

Indexed keywords

ACID PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN;

ACID PHOSPHATASE BLOOD LEVEL; ADULT; ANTIGEN DETECTION; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PROSTATE CANCER; RIB;

ACID PHOSPHATASE; ADENOCARCINOMA; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0031845865     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199808000-00001     Document Type: Article

References (12)

1. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989;142:1011-7.
2. Leibman BD, Dillioglugil O, Wheeler TM, Scardino PT. Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Cancer 1995;76:2530-4.
3. Goldrath DE, Messing EM. Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy. J Urol 1989;142:1082-4.
4. Takayama TK, Krieger JN, True LD, Lange PH. Recurrent prostate cancer despite undetectable prostate specific antigen. J Urol 1992;148:1541-2.
5. Oefelein MG, Smith N, Carter M, Dalton D, Schaeffer A. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J Urol 1995;154:2128-31.
6. Lange PH, Ercole CJ, Lightner DJ, Fraley EF, Vessella R. The value of serum prostate specific antigen determination before and after radical prostatectomy. J Urol 1989;141:873-9.
7. Ercole CJ, Lange PH. The relative value of prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) serum determination in the management of carcinoma of the prostate (CAP) [Abstract 368]. J Urol 1987;137:195A.
8. Ahmann FR, Schifman RB. Prospective comparison between serum monoclonal PSA and acid phosphatase measurements in metastatic prostate cancer. J Urol 1987;137:431-4.
9. Aihara M, Lebovitz RM, Wheeler TM, Kinner BM, Ohori M, Scardino PT. Prostate specific antigen and Gleason grade: an immunohistochemical study of the prostate cancer. J Urol 1994;151:1558-64.
10. Prestidge BR, Kaplan I, Cox RS, Bagshaw MA. Predictors of survival after a positive post-irradiation prostate biopsy. Int J Radiat Oncol Biol Phys 1994;28:17-22.
11. Nadji M, Tabei SZ, Castro A, et al. Prostatic specific antigen: an immunohistologic marker for prostatic neoplasms. Cancer 1981;48:1229-32.
12. Qui SD, Young CYF, Bilhartz DL, Prescott JL, Farrow GM, He WW, Tindall DJ. In-situ hybridization of prostate specific antigen mRNA in human prostate. J Urol 1990;144:1550-6.